奥巴马狭隘政治疑虑左右新美中印关系

伴随着奥巴马转败为胜,入主白宫,温家宝归隐,重量级人物习近平的走马上任,这一切将在未来导致全球政治不断变化,亚洲也将随之涟漪频频。

与印度的关系对于再度连任的奥巴马来说并不是唯一的挑战,印度完全处于美国选举之外延,印度也只能说那些所谓的保护主义的倾向限于选举演说,它终将变成一道又一道成文的法规,最终督促着奥巴马去实施。

奥巴马必须对他的美国公民信守诺言。当他变得不得不去另辟蹊径时,印度工业的迅速发展将为其打开一个更大的空间。按时非常不幸的是,不论是奥巴马还是罗姆尼在他们的竞选演说中竟然对印度只字未提。这成为了当今世界最为典型的政治狭隘的表现。

著名政治评论员C. Raja Mohan先生在《印度快报》上发表文章写道,“获得连任的美国总统奥巴马建议美国重返亚洲。在他当选以后的第一个旅程当中,他安排自己到访柬埔寨参加EAS,并且在此之后到缅甸、泰国做了短暂的停留,这是中国的两个陆地邻国。显然,美国非常明确地展示了它不希望中国能够中和其外缘”。

对于加强美印战略伙伴关系而言,两国之间举行的唯一为人所知的会议,仅仅停留在了生产仿制药品,确保在美国医疗保健系统应用的层面上。

“在美国这样的一个地球上最为富有的国家,不应该因为疾病或者是以外事故给家庭带来经济上的损失”奥巴马如是说。这是一个十分简单的句子,正式这几句话几乎概括了今年奥巴马在经历了竞选以后的全部政治主题。然而,他并没有考虑发展中国家的患者和消费者。

奥巴马,如果他忽视了那些来自新德里的声音,相信他无法在家中独自去推行他那些所谓的“奥巴马的关注”。

在全球范围内美国是最大的制药市场,其所销售药物的市场总额达800亿美元,而国内75%药物需求也都依赖于此。印度制药工厂占据了其中10%的市场份额。美国将继续依赖于印度出口的那些物美价廉的药剂。

而印度生命科学专家指出:“由于价位压力,美国诸多医疗保健供应商将毫无迟疑地选择印度生产的可适用仿制药品,这将无形中增加美国药品市场对于印度的客观需要。名列印度前20位的药物公司在美国市场已经根深蒂固,并且还将进一步扩大他们的影响力和价值”。

Obama politics feared to become parochial in shaping up new relationship with India and China

With President Obama bouncing back in the White House after a convincing victory, and Wen Jiabao making place for the next Party chief, Xi Jinping, the changing scenario of global politics is sure to take a while before the ripples are felt in Asia.

The relationship with India is not really one of the challenges that face President Barack Obama in his second term. With his stand on out-sourcing during the presidential campaign, India can only fool itself that the rhetoric on protectionist tendencies was limited to electoral speeches. It just might turn out to be a policy that Obama is forced to follow. If Obama has to keep his promise to the American voters, he will have to look the other way when the Indian industry pushes him for greater space. Unfortunately, India did not figure in the electoral speeches made by President Obama or even by Mitt Romney during the entire campaign. This seems a clear indicator of how parochial politics is becoming in recent times.

Eminent political commentator, Mr. C. Raja Mohan writes in Indian Express, “The re-election of Barack Obama as President of US suggests that the American pivot to Asia will continue. In his first trip abroad after the elections, Obama is travelling to Cambodia to attend the EAS and making stops in Myanmar and Thailand, two continental neighbours of China. The US is quite clearly unwilling to let China neutralize its Asian periphery.”

As far as the strengthening of Indo-US strategic partnership is concerned, perhaps the only common meeting ground is the production of generic drugs and their use in the American health care system.

During the 2008 Presidential Campaign, Barack Obama promised to “prevent drug companies from blocking generic drugs from consumers.”

“Here in America — in the wealthiest nation on Earth — no illness or accident should lead to any family’s financial ruin,” Obama said. That single sentence was a compelling invocation of nearly every political theme Obama has presented on the campaign trail this year. However, he failed to include the patients/consumers of the developing world.

Obama will not be able to push Obamacare at home in isolation and ignore the voices from New Delhi.

Globally, the US is the largest market for generic drugs totalling $80 billion and with 75% of its health care system dependent on it. Indian companies have cornered approximately 10% share, or $8 billion of this market. The US will continue to depend on India for export of quality generics at affordable prices.

Sujay Shetty, leader, pharma and life sciences, PwC India, says, “Amid pricing pressures, US healthcare providers will push for an enhanced use of generics, which will increase the market for Indian pharma companies. The top 20 domestic companies are already entrenched in the US markets, and will be able to grow their volume as well as value shares, further.”

The AsiaN 编辑局 news@theasian.asia

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>